Drug Shows Promise in Prostate Cancer Spread to Bone, University of Michigan Comprehensive Cancer Center Study

A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers. About two-thirds of patients treated with cabozantinib had improvements on their bone scans, with 12 percent seeing complete resolution of uptake on bone scan. Bone scans assess the degree to which cancer is in the bone; improvements on these scans suggest a response to the drug.